FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3184408889> ?p ?o ?g. }

• W3184408889 endingPage "100040" @default.
• W3184408889 startingPage "100040" @default.
• W3184408889 abstract "To evaluate the safety and preliminary efficacy of THR-687 in patients with center-involved diabetic macular edema (DME).Phase 1, open-label, multicenter, 3 + 3 dose-escalation study with 3-month follow-up.Patients 18 years of age or older with visual impairment resulting from DME.Single intravitreal injection of THR-687 (0.4 mg, 1.0 mg, or 2.5 mg).The primary outcome measure was the incidence of dose-limiting toxicities (DLTs). The secondary outcome measure was the incidence of adverse events (AEs), including the occurrence of laboratory abnormalities. Exploratory outcome measures included changes from baseline in best-corrected visual acuity (BCVA) and central subfield thickness (CST), assessments of ischemia and leakage on fluorescein angiography, and THR-687 levels in plasma.Twelve patients were treated: 3 patients received 0.4 mg of THR-687, 3 patients received 1.0 mg of THR-687, and 6 patients received 2.5 mg of THR-687. Most patients were men (9/12 patients). Their mean age was 57.8 years. No DLTs or serious AEs were reported at any of the dose levels tested. Overall, 9 AEs in the study eye were reported for 5 of 12 patients. Of those, 4 AEs in 3 of 12 patients were deemed treatment related by the investigator, all of which were mild, started on the day of the injection, and had resolved within 28 days without treatment. Overall, mean gains from baseline in BCVA were observed at all study visits with a rapid onset (7.2 Early Treatment Diabetic Retinopathy Study [ETDRS] letters at day 7) and a durability up to the end of the study (8.3 ETDRS letters at month 3). A mean decrease in CST was observed up to month 1. Overall, the mean BCVA gains and CST decreases were highest at the highest THR-687 dose level tested. THR-687 was undetectable in plasma at 7 days after the injection.At all dose levels tested, a single intravitreal injection of THR-687 was safe and well tolerated. Preliminary efficacy was observed by a rapid gain in BCVA with 3 months' durability and a decrease in CST up to 1 month after the injection." @default.
• W3184408889 created "2021-08-02" @default.
• W3184408889 creator A5002231528 @default.
• W3184408889 creator A5013760750 @default.
• W3184408889 creator A5018888370 @default.
• W3184408889 creator A5026181496 @default.
• W3184408889 creator A5035499225 @default.
• W3184408889 creator A5035700046 @default.
• W3184408889 creator A5044390932 @default.
• W3184408889 creator A5046104318 @default.
• W3184408889 creator A5090864408 @default.
• W3184408889 date "2021-09-01" @default.
• W3184408889 modified "2023-10-13" @default.
• W3184408889 title "Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema" @default.
• W3184408889 cites W1576773659 @default.
• W3184408889 cites W1782108791 @default.
• W3184408889 cites W1829715784 @default.
• W3184408889 cites W1843322974 @default.
• W3184408889 cites W1851754610 @default.
• W3184408889 cites W1972102480 @default.
• W3184408889 cites W1982901421 @default.
• W3184408889 cites W1984038456 @default.
• W3184408889 cites W2005409914 @default.
• W3184408889 cites W2015050458 @default.
• W3184408889 cites W2016517388 @default.
• W3184408889 cites W2161279821 @default.
• W3184408889 cites W2169906117 @default.
• W3184408889 cites W2169961704 @default.
• W3184408889 cites W2226585534 @default.
• W3184408889 cites W2234307896 @default.
• W3184408889 cites W2289200040 @default.
• W3184408889 cites W2333755504 @default.
• W3184408889 cites W2397477141 @default.
• W3184408889 cites W2560206371 @default.
• W3184408889 cites W2591137745 @default.
• W3184408889 cites W2605619962 @default.
• W3184408889 cites W2616361514 @default.
• W3184408889 cites W2766315223 @default.
• W3184408889 cites W2777721386 @default.
• W3184408889 cites W2789784671 @default.
• W3184408889 cites W2886062143 @default.
• W3184408889 cites W2901872475 @default.
• W3184408889 cites W2942447515 @default.
• W3184408889 cites W2976376778 @default.
• W3184408889 cites W3022489568 @default.
• W3184408889 cites W3041720076 @default.
• W3184408889 cites W3189920043 @default.
• W3184408889 doi "https://doi.org/10.1016/j.xops.2021.100040" @default.
• W3184408889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36247818" @default.
• W3184408889 hasPublicationYear "2021" @default.
• W3184408889 type Work @default.
• W3184408889 sameAs 3184408889 @default.
• W3184408889 citedByCount "11" @default.
• W3184408889 countsByYear W31844088892020 @default.
• W3184408889 countsByYear W31844088892021 @default.
• W3184408889 countsByYear W31844088892022 @default.
• W3184408889 countsByYear W31844088892023 @default.
• W3184408889 crossrefType "journal-article" @default.
• W3184408889 hasAuthorship W3184408889A5002231528 @default.
• W3184408889 hasAuthorship W3184408889A5013760750 @default.
• W3184408889 hasAuthorship W3184408889A5018888370 @default.
• W3184408889 hasAuthorship W3184408889A5026181496 @default.
• W3184408889 hasAuthorship W3184408889A5035499225 @default.
• W3184408889 hasAuthorship W3184408889A5035700046 @default.
• W3184408889 hasAuthorship W3184408889A5044390932 @default.
• W3184408889 hasAuthorship W3184408889A5046104318 @default.
• W3184408889 hasAuthorship W3184408889A5090864408 @default.
• W3184408889 hasBestOaLocation W31844088891 @default.
• W3184408889 hasConcept C118487528 @default.
• W3184408889 hasConcept C120665830 @default.
• W3184408889 hasConcept C121332964 @default.
• W3184408889 hasConcept C126322002 @default.
• W3184408889 hasConcept C134018914 @default.
• W3184408889 hasConcept C197934379 @default.
• W3184408889 hasConcept C2778257484 @default.
• W3184408889 hasConcept C2779829184 @default.
• W3184408889 hasConcept C2780248432 @default.
• W3184408889 hasConcept C2780886150 @default.
• W3184408889 hasConcept C2985127711 @default.
• W3184408889 hasConcept C555293320 @default.
• W3184408889 hasConcept C61511704 @default.
• W3184408889 hasConcept C71924100 @default.
• W3184408889 hasConceptScore W3184408889C118487528 @default.
• W3184408889 hasConceptScore W3184408889C120665830 @default.
• W3184408889 hasConceptScore W3184408889C121332964 @default.
• W3184408889 hasConceptScore W3184408889C126322002 @default.
• W3184408889 hasConceptScore W3184408889C134018914 @default.
• W3184408889 hasConceptScore W3184408889C197934379 @default.
• W3184408889 hasConceptScore W3184408889C2778257484 @default.
• W3184408889 hasConceptScore W3184408889C2779829184 @default.
• W3184408889 hasConceptScore W3184408889C2780248432 @default.
• W3184408889 hasConceptScore W3184408889C2780886150 @default.
• W3184408889 hasConceptScore W3184408889C2985127711 @default.
• W3184408889 hasConceptScore W3184408889C555293320 @default.
• W3184408889 hasConceptScore W3184408889C61511704 @default.
• W3184408889 hasConceptScore W3184408889C71924100 @default.
• W3184408889 hasIssue "3" @default.
• W3184408889 hasLocation W31844088891 @default.

• next